Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: A randomized prospective study

Drugs in R and D

Volumn 11, Issue 1, 2011, Pages 61-75

  Lissy, Michael ^a   Ode, Marité ^b   Roth, Karsten ^b  

^a Nuvisan GmbH   (Germany)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

Epoetin alfa; pharmacodynamics; pharmacokinetics

Indexed keywords

FERRO SANOL DUODENA; FERROGLYCINE SULFATE; HEMOGLOBIN; HEXAL; IBUPROFEN; IRON COMPLEX; PARACETAMOL; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FEVER; DRUG MARKETING; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; EUROPE; HEMATOCRIT; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SINGLE BLIND PROCEDURE; STEADY STATE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 79953154625     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11588270-000000000-00000     Document Type: Article

References (22)

1. Graber SE, Krantz SB. Erythropoietin and the control of red cell production. Annu Rev Med 1978;29:51-66
2. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43(8):649-59 (Pubitemid 39264162)
3. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetinassociated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48(8):1754-62
4. Cheung WK, Natarajan J, Sanders M, et al. Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers. Biopharm Drug Dispos 2000;21(6):211-9 (Pubitemid 32396644)
5. ®: US prescribing information. Thousand Oaks (CA): Amgen Inc., 2010
6. ®: US prescribing information. Raritan (NJ): Centocor Ortho Biotech Products, L. P., 2009
7. Rhodes CT. Generic substitution: does interchangeability mean equality of all functional relevant attributes? Clin Res Reg Affairs 1995;12(4):267-72
8. Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa aftermultiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol 2009;9:10
9. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoietin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Disease 2002;40:110-8 (Pubitemid 34701218)
10. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001;57(5):411-8 (Pubitemid 33787192)
11. Chow SC, Liu JP. Design and anaylsis of bioavailabitlity and bioequivalence studies. Hong Kong: Marcel Dekker Inc., 1992
12. Data on file, Sandoz Biopharmaceuticals, 2010
13. Deechongkit S, Aoki KH, Park SS, et al. Biophysical comparability of the same protein from different manufacturers: a case study using epoetin-alfa from Epogen and Eprex. J Pharm Sci 2006;95:1931-43 (Pubitemid 44433025)
14. Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol Ther 2009;47(6):391-401
15. Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 2009;83(2):122-30
16. Haag-Weber M, Vetter A, Thyroff-Friesinger U, on behalf of the INJ-Study Group. Therapeutic equivalence, longterm efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009;72(5):380-90
17. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie 2009;32(4):168-74
18. McKoy JM, Robin E, Stonecash RE, et al. Epoetinassociated pure red cell aplasia: past, present, and future considerations. Transfusion 2008 Aug; 48(8):1754-62
19. Evens AM, Bennett CL, Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results fromthe research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol 2005 Sep; 18(3):481-9 (Pubitemid 40425361)
20. Tacey R, Greway A, Smiell J, et al. The detection of antierythropoietin antibodies in human serum and plasma. Part I: validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods 2003 Dec; 283 (1-2): 317-29 (Pubitemid 37501079)
21. Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-3 (Pubitemid 26072120)
22. Linardaki GD, Boki KA, Fertakis A, et al. Pure red cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin. Scand J Rheumatol 1999;28(3):189-91 (Pubitemid 29298017)